Karyopharm Therapeutics Announced That, Following FDA Feedback, The Company Will Be Replacing TSS50, One Of The Co-primary Endpoints In The Phase 3 SENTRY Trial With Abs-TSS
Portfolio Pulse from Benzinga Newsdesk
Karyopharm Therapeutics has announced a change in the co-primary endpoint of its Phase 3 SENTRY trial, replacing TSS50 with Abs-TSS, following FDA feedback. The trial will also increase its sample size to 350 patients, with top-line data expected in the second half of 2025.
October 31, 2024 | 11:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Karyopharm Therapeutics is adjusting its Phase 3 SENTRY trial by changing a co-primary endpoint to Abs-TSS and increasing the sample size to 350 patients, following FDA feedback. This could enhance the trial's statistical power and impact future results.
The change in the trial's endpoint to Abs-TSS and the increase in sample size are proactive measures that align with FDA feedback, potentially improving the trial's outcome reliability. This could positively influence investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100